Literature DB >> 23340677

Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation.

Linn Hege Nilsen1, Caroline Rae, Lars M Ittner, Jürgen Götz, Ursula Sonnewald.   

Abstract

In neurodegenerative diseases including Alzheimer's disease and frontotemporal dementia, the protein tau is hyperphosphorylated and eventually aggregates to develop neurofibrillary tangles. Here, the consequences of tau hyperphosphorylation on both neuronal and astrocytic metabolism and amino-acid neurotransmitter homeostasis were assessed in transgenic mice expressing the pathogenic mutation P301L in the human tau gene (pR5 mice) compared with nontransgenic littermate controls. Mice were injected with the neuronal and astrocytic substrate [1-(13)C]glucose and the astrocytic substrate [1,2-(13)C]acetate. Hippocampus and cerebral cortex extracts were analyzed using (1)H and (13)C nuclear magnetic resonance spectroscopy, gas chromatography-mass spectrometry and high-performance liquid chromatography. The glutamate level was reduced in the hippocampus of pR5 mice, accompanied by reduced incorporation of (13)C label derived from [1-(13)C]glucose in glutamate. In the cerebral cortex, glucose utilization as well as turnover of glutamate, glutamine, and GABA, were increased. This was accompanied by a relative increase in production of glutamate via the pyruvate carboxylation pathway in cortex. Overall, we revealed that astrocytes as well as glutamatergic and GABAergic neurons in the cortex of pR5 mice were in a hypermetabolic state, whereas in the hippocampus, where expression levels of mutant human tau are the highest, glutamate homeostasis was impaired.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340677      PMCID: PMC3652703          DOI: 10.1038/jcbfm.2012.212

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  39 in total

1.  Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure.

Authors:  Daniel Kondziella; Eiliv Brenner; Elvar M Eyjolfsson; Katarina Ryden Markinhuhta; Maria L Carlsson; Ursula Sonnewald
Journal:  Neuropsychopharmacology       Date:  2005-12-14       Impact factor: 7.853

Review 2.  Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?

Authors:  Jürgen Götz; Lars M Ittner; Stefan Kins
Journal:  J Neurochem       Date:  2006-06-19       Impact factor: 5.372

3.  Tau is a candidate gene for chromosome 17 frontotemporal dementia.

Authors:  P Poorkaj; T D Bird; E Wijsman; E Nemens; R M Garruto; L Anderson; A Andreadis; W C Wiederholt; M Raskind; G D Schellenberg
Journal:  Ann Neurol       Date:  1998-06       Impact factor: 10.422

4.  Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice.

Authors:  Della C David; Susanne Hauptmann; Isabel Scherping; Katrin Schuessel; Uta Keil; Patrizia Rizzu; Rivka Ravid; Stefan Dröse; Ulrich Brandt; Walter E Müller; Anne Eckert; Jürgen Götz
Journal:  J Biol Chem       Date:  2005-04-14       Impact factor: 5.157

5.  Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

Authors:  L Mosconi; W-H Tsui; S De Santi; J Li; H Rusinek; A Convit; Y Li; Madhu Boppana; M J de Leon
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

Review 6.  The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer.

Authors:  Lasse K Bak; Arne Schousboe; Helle S Waagepetersen
Journal:  J Neurochem       Date:  2006-06-19       Impact factor: 5.372

7.  Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.

Authors:  Karin Boekhoorn; Dick Terwel; Barbara Biemans; Peter Borghgraef; Olof Wiegert; Ger J A Ramakers; Koos de Vos; Harm Krugers; Takami Tomiyama; Hiroshi Mori; Marian Joels; Fred van Leuven; Paul J Lucassen
Journal:  J Neurosci       Date:  2006-03-29       Impact factor: 6.167

8.  18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients.

Authors:  Yong Jeong; Sang Soo Cho; Jung Mi Park; Sue J Kang; Jae Sung Lee; Eunjoo Kang; Duk L Na; Sang Eun Kim
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

9.  Cerebral glucose metabolism in patients with frontotemporal dementia.

Authors:  K Ishii; S Sakamoto; M Sasaki; H Kitagaki; S Yamaji; M Hashimoto; T Imamura; T Shimomura; N Hirono; E Mori
Journal:  J Nucl Med       Date:  1998-11       Impact factor: 10.057

10.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more
  32 in total

Review 1.  Mitochondrial function in ageing: coordination with signalling and transcriptional pathways.

Authors:  Fei Yin; Harsh Sancheti; Zhigang Liu; Enrique Cadenas
Journal:  J Physiol       Date:  2015-09-16       Impact factor: 5.182

2.  Activity-Dependent Reconnection of Adult-Born Dentate Granule Cells in a Mouse Model of Frontotemporal Dementia.

Authors:  Julia Terreros-Roncal; Miguel Flor-García; Elena P Moreno-Jiménez; Noemí Pallas-Bazarra; Alberto Rábano; Nirnath Sah; Henriette van Praag; Damiana Giacomini; Alejandro F Schinder; Jesús Ávila; Maria Llorens-Martín
Journal:  J Neurosci       Date:  2019-05-27       Impact factor: 6.167

3.  In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy.

Authors:  Rachelle Crescenzi; Catherine DeBrosse; Ravi Prakash Reddy Nanga; Sanjana Reddy; Mohammed Haris; Hari Hariharan; Michiyo Iba; Virginia M Y Lee; John A Detre; Arijitt Borthakur; Ravinder Reddy
Journal:  Neuroimage       Date:  2014-07-05       Impact factor: 6.556

Review 4.  Energy metabolism and inflammation in brain aging and Alzheimer's disease.

Authors:  Fei Yin; Harsh Sancheti; Ishan Patil; Enrique Cadenas
Journal:  Free Radic Biol Med       Date:  2016-05-03       Impact factor: 7.376

5.  Synaptic Adhesion Molecule Pcdh-γC5 Mediates Synaptic Dysfunction in Alzheimer's Disease.

Authors:  Yanfang Li; Zhicai Chen; Yue Gao; Gaojie Pan; Honghua Zheng; Yunwu Zhang; Huaxi Xu; Guojun Bu; Hui Zheng
Journal:  J Neurosci       Date:  2017-08-21       Impact factor: 6.167

Review 6.  Astrocyte and Alzheimer's disease.

Authors:  Zhiyou Cai; Cheng-Qun Wan; Zhou Liu
Journal:  J Neurol       Date:  2017-08-18       Impact factor: 4.849

7.  AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy.

Authors:  A Borreca; V Latina; V Corsetti; S Middei; S Piccinin; F Della Valle; R Bussani; M Ammassari-Teule; R Nisticò; P Calissano; G Amadoro
Journal:  Mol Neurobiol       Date:  2018-03-05       Impact factor: 5.590

Review 8.  Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2013-07-03       Impact factor: 3.911

Review 9.  Anesthesia and tau pathology.

Authors:  Robert A Whittington; Alexis Bretteville; Maya F Dickler; Emmanuel Planel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-03-25       Impact factor: 5.067

10.  Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a 13C-NMR study.

Authors:  Harsh Sancheti; Ishan Patil; Keiko Kanamori; Roberta Díaz Brinton; Wei Zhang; Ai-Ling Lin; Enrique Cadenas
Journal:  J Cereb Blood Flow Metab       Date:  2014-08-06       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.